T1	intervention 11 28	physical exercise
T2	eligibility 444 495	breast cancer patients during adjuvant chemotherapy
T3	No-of-participants 501 504	130
T4	duration 598 605	12-week
T5	duration 646 653	18-week
T6	outcome-Measure 709 754	Serum IL-6, IL-1ra, and the IL-6/IL-1ra ratio
T7	outcome 890 974	increases in IL-6 and IL-6/IL-1ra ratio during chemotherapy and decreases afterwards
T8	outcome 1063 1102	Changes in total cancer-related fatigue
T9	outcome 1312 1330	Changes in fatigue
T10	outcome 1361 1392	changes in inflammatory markers
